AIM ImmunoTech Inc.
AIM
$2.55
-$0.05-1.92%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -39.80% | -24.35% | -15.84% | -1.55% | 19.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -39.80% | -24.35% | -15.84% | -1.55% | 19.64% |
| Cost of Revenue | -39.66% | -34.00% | -26.19% | 20.00% | -- |
| Gross Profit | -39.86% | -20.98% | -13.13% | -5.52% | -14.88% |
| SG&A Expenses | -49.63% | -44.71% | -34.59% | 46.46% | 66.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -47.37% | -46.93% | -37.91% | 18.80% | 44.49% |
| Operating Income | 47.42% | 47.06% | 38.05% | -18.97% | -44.68% |
| Income Before Tax | 42.36% | 51.13% | 40.20% | -15.18% | -44.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 42.36% | 51.13% | 40.20% | -15.18% | -44.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 42.36% | 51.13% | 40.20% | -15.18% | -44.98% |
| EBIT | 47.42% | 47.06% | 38.05% | -18.97% | -44.68% |
| EBITDA | 47.80% | 47.41% | 38.36% | -19.73% | -45.80% |
| EPS Basic | 56.75% | 61.62% | 48.00% | -10.34% | -42.09% |
| Normalized Basic EPS | 56.34% | 61.46% | 48.67% | -13.05% | -43.28% |
| EPS Diluted | 56.75% | 61.62% | 48.38% | -9.23% | -40.56% |
| Normalized Diluted EPS | 56.34% | 61.46% | 48.67% | -13.05% | -43.28% |
| Average Basic Shares Outstanding | 30.69% | -1.46% | -11.66% | -19.11% | -23.56% |
| Average Diluted Shares Outstanding | 30.69% | -1.46% | -11.66% | -19.11% | -23.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |